NASDAQ:ASBP Aspire Biopharma (ASBP) Stock Price, News & Analysis $9.06 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$9.06 0.00 (0.00%) As of 07:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Aspire Biopharma Stock (NASDAQ:ASBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aspire Biopharma alerts:Sign Up Key Stats Today's Range$9.06▼$9.3850-Day Range$5.61▼$9.2552-Week Range$3.31▼$562.92Volume26,785 shsAverage Volume31,020 shsMarket Capitalization$12.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aspire Biopharma Inc. is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions. The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis. In addition to epinephrine, Aspire has in-licensed a portfolio of novel PDE3/4 inhibitor compounds intended for maintenance therapy in chronic obstructive pulmonary disease (COPD) and severe asthma. Aspire’s development strategy emphasizes efficient clinical pathways and leveraging existing safety data to accelerate regulatory review. Founded in 2007 and headquartered in Henderson, Nevada, Aspire Biopharma serves the U.S. market while exploring international licensing and distribution opportunities. The company maintains partnerships with contract development and manufacturing organizations (CDMOs) to support scalable production of its inhalation devices and formulations. Aspire’s leadership team combines expertise in pharmaceutical R&D, regulatory affairs, and pulmonary device engineering to drive its product pipeline toward late-stage clinical and market readiness. Through strategic collaborations and targeted R&D investments, Aspire aims to address unmet medical needs in emergency medicine and chronic respiratory care. By focusing on inhaled delivery of both established and novel compounds, the company seeks to offer differentiated treatment options that improve patient outcomes and streamline acute care interventions.AI Generated. May Contain Errors. Read More Aspire Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreASBP MarketRank™: Aspire Biopharma scored higher than 16% of companies evaluated by MarketBeat, and ranked 451st out of 484 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAspire Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Aspire Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aspire Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aspire Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.27% of the float of Aspire Biopharma has been sold short.Short Interest Ratio / Days to CoverAspire Biopharma has a short interest ratio ("days to cover") of 1.81, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aspire Biopharma has recently decreased by 34.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAspire Biopharma does not currently pay a dividend.Dividend GrowthAspire Biopharma does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.75 News SentimentAspire Biopharma has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Discretionary companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aspire Biopharma this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Aspire Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aspire Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Aspire Biopharma is held by insiders.Percentage Held by Institutions19.17% of the stock of Aspire Biopharma is held by institutions.Read more about Aspire Biopharma's insider trading history. Receive ASBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aspire Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASBP Stock News HeadlinesAspire-Lakewood Launches $10 Million Share Repurchase ProgramSeptember 9, 2026 | tipranks.comAspire Biopharma Holdings, Inc.: Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase ProgramSeptember 9, 2026 | finanznachrichten.deHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 14 at 1:00 AM | Stansberry Research (Ad)Aspire Biopharma Changes Name to Aspire-Lakewood Holdings Inc.September 8, 2026 | usatoday.comAspire Biopharma Renamed Aspire-Lakewood Holdings, Inc.September 8, 2026 | tipranks.comAspire Biopharma Holdings Inc ASBPAugust 18, 2026 | morningstar.comMAspire Biopharma Holdings, Inc.: Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMBJuly 21, 2026 | finanznachrichten.deAspire Biopharma Updates Public Warrant Exercise TermsJuly 20, 2026 | tipranks.comSee More Headlines ASBP Stock Analysis - Frequently Asked Questions How have ASBP shares performed this year? Aspire Biopharma's stock was trading at $158.28 at the beginning of the year. Since then, ASBP stock has decreased by 94.3% and is now trading at $9.06. How were Aspire Biopharma's earnings last quarter? Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) posted its quarterly earnings data on Friday, November, 14th. The company reported ($48.00) EPS for the quarter. The company earned $0 million during the quarter. When did Aspire Biopharma's stock split? Aspire Biopharma's stock reverse split before market open on Monday, May 11th 2026.The 1-30 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aspire Biopharma? Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/14/2025Today9/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Automobile Components Sub-IndustryAutomotive Parts & Equipment Current SymbolNASDAQ:ASBP Previous SymbolNASDAQ:PWUP CIK1847345 Webaspirebiolabs.com Phone(561) 704-8527FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($69.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.48 million Net Margins-11,362.21% Pretax Margin-11,361.18% Return on EquityN/A Return on Assets-177.59% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.82 Sales & Book Value Annual Sales$10 thousand Price / Sales1,268.40 Cash FlowN/A Price / Cash FlowN/A Book Value($54.19) per share Price / Book-0.17Miscellaneous Outstanding Shares1,400,000Free Float1,322,000Market Cap$12.68 million OptionableN/A Beta0.17 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ASBP) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
